Biomea Fusion (BMEA) Competitors $1.68 +0.09 (+5.66%) Closing price 03:59 PM EasternExtended Trading$1.69 +0.01 (+0.83%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMEA vs. HRTX, RGNX, VERV, TECX, ORKA, MREO, BNTC, AURA, CYRX, and RNACShould you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Heron Therapeutics (HRTX), REGENXBIO (RGNX), Verve Therapeutics (VERV), Tectonic Therapeutic (TECX), Oruka Therapeutics (ORKA), Mereo BioPharma Group (MREO), Benitec Biopharma (BNTC), Aura Biosciences (AURA), Cryoport (CYRX), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry. Biomea Fusion vs. Heron Therapeutics REGENXBIO Verve Therapeutics Tectonic Therapeutic Oruka Therapeutics Mereo BioPharma Group Benitec Biopharma Aura Biosciences Cryoport Cartesian Therapeutics Biomea Fusion (NASDAQ:BMEA) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking. Is BMEA or HRTX more profitable? Biomea Fusion has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.31%. Heron Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% Heron Therapeutics -20.31%N/A -12.72% Do analysts prefer BMEA or HRTX? Biomea Fusion currently has a consensus price target of $23.91, suggesting a potential upside of 1,323.16%. Heron Therapeutics has a consensus price target of $5.67, suggesting a potential upside of 207.97%. Given Biomea Fusion's higher possible upside, equities research analysts plainly believe Biomea Fusion is more favorable than Heron Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, BMEA or HRTX? Heron Therapeutics has higher revenue and earnings than Biomea Fusion. Heron Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$3.84-0.44Heron Therapeutics$144.29M1.94-$110.56M-$0.09-20.44 Do insiders and institutionals have more ownership in BMEA or HRTX? 96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by insiders. Comparatively, 5.8% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer BMEA or HRTX? Heron Therapeutics received 607 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 68.87% of users gave Heron Therapeutics an outperform vote while only 68.54% of users gave Biomea Fusion an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes6168.54% Underperform Votes2831.46% Heron TherapeuticsOutperform Votes66868.87% Underperform Votes30231.13% Which has more volatility and risk, BMEA or HRTX? Biomea Fusion has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Does the media prefer BMEA or HRTX? In the previous week, Heron Therapeutics had 4 more articles in the media than Biomea Fusion. MarketBeat recorded 4 mentions for Heron Therapeutics and 0 mentions for Biomea Fusion. Heron Therapeutics' average media sentiment score of 0.83 beat Biomea Fusion's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Biomea Fusion Neutral Heron Therapeutics Positive SummaryHeron Therapeutics beats Biomea Fusion on 10 of the 17 factors compared between the two stocks. Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMEA vs. The Competition Export to ExcelMetricBiomea FusionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.12M$6.44B$5.29B$7.35BDividend YieldN/A3.25%5.12%4.31%P/E Ratio-0.426.8821.7117.77Price / SalesN/A231.36379.3997.68Price / CashN/A65.6738.2234.64Price / Book0.355.916.443.98Net Income-$117.25M$142.72M$3.21B$247.44M7 Day Performance-2.89%7.98%5.24%4.44%1 Month Performance-33.33%-13.91%-9.49%-7.73%1 Year Performance-85.39%-9.98%11.01%1.28% Biomea Fusion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMEABiomea Fusion2.6783 of 5 stars$1.68+5.7%$23.91+1,323.2%-86.7%$63.12MN/A-0.4250Gap DownHRTXHeron Therapeutics3.4805 of 5 stars$1.96-6.7%$5.67+189.1%-37.2%$298.57M$144.29M-10.89300Positive NewsRGNXREGENXBIO4.7148 of 5 stars$5.93-5.7%$32.78+452.7%-64.8%$297.01M$83.33M-1.18370Analyst ForecastAnalyst RevisionNews CoveragePositive NewsVERVVerve Therapeutics3.0766 of 5 stars$3.34-7.7%$20.67+518.8%-36.8%$296.58M$32.33M-1.36110Analyst ForecastOptions VolumeNews CoverageHigh Trading VolumeTECXTectonic Therapeutic2.8122 of 5 stars$15.53-0.6%$77.75+400.6%N/A$289.84MN/A-2.64120Short Interest ↑Positive NewsGap DownORKAOruka Therapeutics3.0966 of 5 stars$7.62-2.7%$39.86+423.1%N/A$285.30MN/A-1.22N/AUpcoming EarningsNews CoveragePositive NewsHigh Trading VolumeMREOMereo BioPharma Group1.8594 of 5 stars$1.83-8.0%$7.71+321.5%-20.8%$283.92M$1M-30.5040Gap DownHigh Trading VolumeBNTCBenitec Biopharma2.2038 of 5 stars$12.02-2.4%$24.43+103.2%+185.6%$281.88M$80,000.00-7.9620Short Interest ↑AURAAura Biosciences1.9894 of 5 stars$5.52+1.7%$22.75+312.1%-25.6%$277.24MN/A-3.1950Short Interest ↑CYRXCryoport2.5064 of 5 stars$5.49+2.6%$11.83+115.5%-67.0%$274.01M$228.39M-1.621,020Analyst ForecastGap DownRNACCartesian Therapeutics1.7207 of 5 stars$10.11+1.1%$42.14+316.8%-43.7%$261.92M$38.91M-0.1964 Related Companies and Tools Related Companies HRTX Alternatives RGNX Alternatives VERV Alternatives TECX Alternatives ORKA Alternatives MREO Alternatives BNTC Alternatives AURA Alternatives CYRX Alternatives RNAC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMEA) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
